Atrium Therapeutics Inc(RNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 0.09% | Shs Outstand | 17.1M | Perf Week | -29.04% |
| Market Cap | 0.18B | Forward P/E | - | EPS next Y | -55.14% | Insider Trans | - | Shs Float | 17.1M | Perf Month | -14.87% |
| Enterprise Value | -0.09B | PEG | - | EPS next Q | -0.87 | Inst Own | 83.83% | Short Float | 19.61% | Perf Quarter | -16.65% |
| Income | - | P/S | - | EPS this Y | -2.12% | Inst Trans | -8.18% | Short Ratio | 15.29 | Perf Half Y | -28.75% |
| Sales | - | P/B | 0.83 | EPS next 5Y | -13.39% | ROA | - | Short Interest | 3.35M | Perf YTD | -28.94% |
| Book/sh | 12.54 | P/C | 0.67 | EPS past 3/5Y | -178.43% - | ROE | - | 52W High | -38.22% ($16.77) | Perf Year | - |
| Cash/sh | 15.45 | P/FCF | - | Sales past 3/5Y | 38.09% - | ROIC | - | 52W Low | 0.78% ($10.28) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 10.86% 5.78% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.71 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.73 | EPS Q/Q | -170.95% | Profit Margin | - | RSI (14) | 31.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.73 | Sales Q/Q | 90.97% | SMA20 | -20.5% ($13.03) | Beta | - | Target Price | $25 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/13 | SMA50 | -17.13% ($12.5) | Rel Volume | 1.13 | Prev Close | $10.35 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | 16.75% 350.58% | SMA200 | -20.46% ($13.02) | Avg Volume(3M) | 0.22M | Price | $10.36 |
| IPO | 2020/6/12 | Option/Short | No/Yes | Trades | 2856 | Volume | 247,400 | Change | 0.1% |
Company
RNA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A US biotech company developing precision RNA therapeutics that target hereditary heart diseases. Leveraging a non-viral siRNA delivery platform that combines the tissue selectivity of antibody/targeted ligands with the precision of oligonucleotides, the company is building a drug pipeline in the field of precision cardiology.
Over the past 1 year, on the lower side
38% below its 1-year high.
RNA makes money exceptionally well
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -2.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 83.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
JSML 0.00%
GNOM 0.00%
EVNT 0.00%
FSEG 0.00%
MRGR 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VXUS 164.4B
BNDX 82.7B
SCHF 69.4B
IXUS 59.8B
BIV 28.6BIt ranks #4 in the industry
Based on market cap of $177M.
RNA $177M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is RNA?
RNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNA?
The market cap of RNA is approximately $177M, ranking 4,209 within its sector.
What is the 52-week high and low for RNA?
RNA has recorded a 52-week high of $16.77 and a low of $10.28.
